Angelini Ventures
Headquarter
Singapore
Milestones
Founded: 2020
Invested: 2025
CO-Founder and CEO
Tan Yann Chong, Founder & CEO
Vertical
Biotech
Board Participation
Elia Stupka, Board Member
Lola Buono, Observer Member
Nuevocor is a biotechnology company that is pioneering an innovative pathway-centric approach to developing functional cures for heart conditions known as cardiomyopathies. By harnessing our PrOSIA™ mechanobiology platform, Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases.
Nuevocor's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables us to extend our impact to broader patient populations
Related news: